Staying on 0.5mg Wegovy: when it makes sense and when it doesn't

Where 0.5mg sits in the Wegovy schedule, and why that matters

The Wegovy titration ladder runs from 0.25mg up through 0.5mg, 1.0mg, 1.7mg and then 2.4mg, with each step lasting roughly four weeks. The full Wegovy dosing schedule is designed this way deliberately: the lower doses let your body adjust to semaglutide before you reach the level shown to produce the most substantial average weight loss in trials.

At 0.5mg, you are past the purely introductory 0.25mg phase. Your system has had some exposure to the medicine. But 0.5mg is still considered a titration dose rather than a therapeutic target. The STEP 1 trial that underpinned Wegovy's licence, published in the New England Journal of Medicine, ran participants up to 2.4mg, the 15% average weight reduction reported in that study reflects the full escalation, not time spent at 0.5mg. Understanding this distinction is important before you decide to stay put.

That said, "stay at 0.5mg" is not the same as "abandon the titration plan entirely." It may mean pausing the escalation temporarily, not permanently. The reasons for that pause are what your prescriber needs to explore with you. Some people spend six or eight weeks at 0.5mg because side effects were noticeable at the four-week mark; others are waiting until life is less disrupted, a holiday or a heavy work period passes, before moving up. The medicine does not stop working because you take an extra few weeks. It does, however, stop being optimised if you stay at a low dose indefinitely without a clear clinical reason.

The case for extending your time at 0.5mg, and its limits

There are genuine clinical situations where remaining at 0.5mg for longer than the standard four weeks is the sensible choice. Persistent nausea, vomiting or disrupted digestion after a dose increase are the most common reasons a prescriber might recommend holding at the current level. Staying on a lower dose of Wegovy while side effects settle is far preferable to stopping treatment altogether, and it is a recognised clinical approach, not a failure.

If you moved from 0.25mg to 0.5mg and found the jump harder than expected, your prescriber may also use 0.5mg as a longer plateau before the next step to 1.0mg. Side effects with semaglutide are mostly gastrointestinal (nausea, loose stools, indigestion) and they tend to be worst in the first week or two after a dose change, then ease off. Giving that settling period more time is not the same as abandoning progress.

The limit of this approach is that 0.5mg is unlikely to deliver the degree of weight loss most people are hoping for if held indefinitely. Weight loss on semaglutide is dose-dependent; the higher doses reduce appetite more substantially. If you have been at 0.5mg for several months with no further increase and limited progress, that is a conversation worth having with your prescriber about whether the current plan is still serving you, and it is also worth knowing that the titration continues through further increments, including Wegovy 4.8mg, which gives a sense of how much further the schedule can extend. It is also worth knowing that typical time spent at 0.5mg gives a useful reference point for that conversation.

When staying at 0.5mg is not the right answer

There are situations where holding at 0.5mg can quietly undermine the treatment. If side effects have fully settled, you are tolerating the dose well and several weeks have passed, the standard guidance supports moving to 1.0mg. Staying at 0.5mg because of anxiety about the next step, or because of uncertainty about whether it is "allowed," is not a strong clinical reason, and it is the kind of question a prescriber can resolve in one conversation rather than a reason to stall.

It is also worth being honest about what "tolerating 0.5mg well" really means. Some people feel so few side effects at 0.5mg that they assume they are different and will struggle at higher doses. That is not always the case; the side effect profile often stays manageable across the titration as long as the steps are followed at the right pace. How long people typically spend at 1.0mg may give you a sense of what comes next and why that step is usually well-tolerated too.

If you are on Wegovy through a private clinic or pharmacy and feel uncertain about whether to move up or stay put, that is exactly the kind of question aftercare support exists for. At nume, prescribers are available seven days a week precisely because dose questions arise between scheduled reviews. Waiting until a monthly check-in to ask something that is affecting your treatment today is not necessary. Cost context for private treatment (what is included in a transparent price and what is not) is set out on our treatment options page.

How to raise this with your prescriber, and what to bring to the conversation

If you are asking whether you can stay on 0.5mg Wegovy, the most useful thing you can do is be specific about why. Is it side effects, and if so, which ones, how severe and how long have they lasted? Is it a practical reason like travel or a planned procedure? Are you seeing some weight loss and wondering whether to let that continue before increasing? Or is it uncertainty about what the higher doses feel like?

Each of those has a different answer, and a prescriber can only give you the right one if they understand the question. Bring a note of when side effects occur (typically within a day or two of the weekly injection), how long they last and how they affect daily life. If you are using Wegovy through a service that offers clinical review before each repeat order, that review is the natural moment to raise it, not something to navigate around.

You can also read the Patient Information Leaflet that comes with your pen, and the NHS medicines page for semaglutide sets out the titration schedule and side effect profile clearly. Both are worth reading before your prescriber conversation so you arrive with questions rather than gaps. The decision about whether to stay at 0.5mg, move up or pause entirely is clinical, but you are an active participant in it, and that means being informed matters.